|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NR1H2 |
Gene summary for NR1H2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NR1H2 | Gene ID | 7376 |
| Gene name | nuclear receptor subfamily 1 group H member 2 | |
| Gene Alias | LXR-b | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P55055 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7376 | NR1H2 | LZE2D | Human | Esophagus | HGIN | 8.09e-03 | 2.42e-01 | 0.0642 |
| 7376 | NR1H2 | LZE4T | Human | Esophagus | ESCC | 4.08e-14 | 3.38e-01 | 0.0811 |
| 7376 | NR1H2 | LZE7T | Human | Esophagus | ESCC | 5.33e-10 | 5.36e-01 | 0.0667 |
| 7376 | NR1H2 | LZE8T | Human | Esophagus | ESCC | 3.25e-15 | 3.16e-01 | 0.067 |
| 7376 | NR1H2 | LZE20T | Human | Esophagus | ESCC | 1.52e-05 | 1.66e-01 | 0.0662 |
| 7376 | NR1H2 | LZE22D1 | Human | Esophagus | HGIN | 8.83e-03 | 1.55e-01 | 0.0595 |
| 7376 | NR1H2 | LZE22T | Human | Esophagus | ESCC | 4.29e-05 | 5.37e-01 | 0.068 |
| 7376 | NR1H2 | LZE24T | Human | Esophagus | ESCC | 7.40e-30 | 8.11e-01 | 0.0596 |
| 7376 | NR1H2 | LZE21T | Human | Esophagus | ESCC | 1.46e-02 | 2.08e-01 | 0.0655 |
| 7376 | NR1H2 | LZE6T | Human | Esophagus | ESCC | 2.91e-05 | 4.79e-01 | 0.0845 |
| 7376 | NR1H2 | P1T-E | Human | Esophagus | ESCC | 4.90e-14 | 5.47e-01 | 0.0875 |
| 7376 | NR1H2 | P2T-E | Human | Esophagus | ESCC | 1.58e-31 | 5.36e-01 | 0.1177 |
| 7376 | NR1H2 | P4T-E | Human | Esophagus | ESCC | 1.08e-26 | 5.69e-01 | 0.1323 |
| 7376 | NR1H2 | P5T-E | Human | Esophagus | ESCC | 2.44e-14 | 1.89e-01 | 0.1327 |
| 7376 | NR1H2 | P8T-E | Human | Esophagus | ESCC | 1.55e-64 | 1.33e+00 | 0.0889 |
| 7376 | NR1H2 | P9T-E | Human | Esophagus | ESCC | 5.81e-22 | 5.24e-01 | 0.1131 |
| 7376 | NR1H2 | P10T-E | Human | Esophagus | ESCC | 8.68e-43 | 7.94e-01 | 0.116 |
| 7376 | NR1H2 | P11T-E | Human | Esophagus | ESCC | 3.25e-27 | 8.98e-01 | 0.1426 |
| 7376 | NR1H2 | P12T-E | Human | Esophagus | ESCC | 4.34e-25 | 4.13e-01 | 0.1122 |
| 7376 | NR1H2 | P15T-E | Human | Esophagus | ESCC | 2.91e-32 | 6.83e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
| GO:190589725 | Esophagus | HGIN | regulation of response to endoplasmic reticulum stress | 31/2587 | 82/18723 | 5.25e-08 | 2.91e-06 | 31 |
| GO:003133425 | Esophagus | HGIN | positive regulation of protein-containing complex assembly | 61/2587 | 237/18723 | 7.10e-07 | 3.00e-05 | 61 |
| GO:004325427 | Esophagus | HGIN | regulation of protein-containing complex assembly | 94/2587 | 428/18723 | 2.39e-06 | 8.55e-05 | 94 |
| GO:190495120 | Esophagus | HGIN | positive regulation of establishment of protein localization | 73/2587 | 319/18723 | 6.99e-06 | 2.14e-04 | 73 |
| GO:190357320 | Esophagus | HGIN | negative regulation of response to endoplasmic reticulum stress | 18/2587 | 44/18723 | 8.97e-06 | 2.64e-04 | 18 |
| GO:003052220 | Esophagus | HGIN | intracellular receptor signaling pathway | 62/2587 | 265/18723 | 1.63e-05 | 4.50e-04 | 62 |
| GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
| GO:005122220 | Esophagus | HGIN | positive regulation of protein transport | 67/2587 | 303/18723 | 5.13e-05 | 1.22e-03 | 67 |
| GO:003166726 | Esophagus | HGIN | response to nutrient levels | 89/2587 | 474/18723 | 1.41e-03 | 1.64e-02 | 89 |
| GO:00483844 | Esophagus | HGIN | retinoic acid receptor signaling pathway | 11/2587 | 31/18723 | 2.02e-03 | 2.12e-02 | 11 |
| GO:004586126 | Esophagus | HGIN | negative regulation of proteolysis | 68/2587 | 351/18723 | 2.21e-03 | 2.28e-02 | 68 |
| GO:00028325 | Esophagus | HGIN | negative regulation of response to biotic stimulus | 25/2587 | 108/18723 | 5.87e-03 | 4.77e-02 | 25 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
| hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
| hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa049317 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
| hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| NR1H2 | M1MAC | Cervix | ADJ | LRRN3,CPB2-AS1,PTN, etc. | 1.33e-01 |  |
| NR1H2 | M2MAC | Cervix | ADJ | LRRN3,CPB2-AS1,PTN, etc. | 1.88e-01 | |
| NR1H2 | CD8TEXINT | Cervix | ADJ | LRRN3,CPB2-AS1,PTN, etc. | 6.29e-03 | |
| NR1H2 | M1MAC | Cervix | CC | LRRN3,CPB2-AS1,PTN, etc. | 4.87e-02 |  |
| NR1H2 | CD8TCM | Cervix | CC | LRRN3,CPB2-AS1,PTN, etc. | 7.56e-02 | |
| NR1H2 | INMON | Cervix | CC | LRRN3,CPB2-AS1,PTN, etc. | 1.73e-01 | |
| NR1H2 | MON | Cervix | CC | LRRN3,CPB2-AS1,PTN, etc. | 1.54e-01 | |
| NR1H2 | NEUT | Cervix | CC | LRRN3,CPB2-AS1,PTN, etc. | 1.26e-01 | |
| NR1H2 | M2MAC | Cervix | Healthy | LRRN3,CPB2-AS1,PTN, etc. | 1.38e-02 |  |
| NR1H2 | INMON | Cervix | Healthy | LRRN3,CPB2-AS1,PTN, etc. | 2.12e-02 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 4 5 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NR1H2 | SNV | Missense_Mutation | c.796N>T | p.Arg266Cys | p.R266C | P55055 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| NR1H2 | SNV | Missense_Mutation | rs140558724 | c.643N>A | p.Glu215Lys | p.E215K | P55055 | protein_coding | tolerated(0.74) | benign(0.029) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NR1H2 | SNV | Missense_Mutation | rs750204613 | c.376N>T | p.Arg126Trp | p.R126W | P55055 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NR1H2 | SNV | Missense_Mutation | c.1049A>T | p.Asn350Ile | p.N350I | P55055 | protein_coding | deleterious(0) | possibly_damaging(0.881) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NR1H2 | SNV | Missense_Mutation | c.253N>A | p.Glu85Lys | p.E85K | P55055 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NR1H2 | SNV | Missense_Mutation | rs763608025 | c.788N>A | p.Arg263His | p.R263H | P55055 | protein_coding | tolerated(0.1) | benign(0.086) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NR1H2 | SNV | Missense_Mutation | c.254N>C | p.Glu85Ala | p.E85A | P55055 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NR1H2 | SNV | Missense_Mutation | rs771140870 | c.341N>A | p.Ser114Asn | p.S114N | P55055 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| NR1H2 | SNV | Missense_Mutation | c.659C>T | p.Thr220Ile | p.T220I | P55055 | protein_coding | deleterious(0.02) | benign(0.302) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
| NR1H2 | SNV | Missense_Mutation | rs772224466 | c.67N>A | p.Ala23Thr | p.A23T | P55055 | protein_coding | tolerated(0.76) | benign(0) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651470 | DESMOSTEROL | |
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 223366058 | ||
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | GW3965 | CHEMBL59030 | 18800767 | |
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651391 | ||
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | DESMOSTEROL | DESMOSTEROL | 23910990 | |
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | ||
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | VTB-38543 | |||
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651390 | ||
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL3545418 | BMS-779788 | |
| 7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL3545238 | CS-8080 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |